Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
12.17
-0.28 (-2.21%)
At close: Sep 17, 2025, 4:00 PM EDT
12.15
-0.01 (-0.12%)
After-hours: Sep 17, 2025, 7:58 PM EDT
Ocular Therapeutix Stock Forecast
Stock Price Forecast
The 6 analysts that cover Ocular Therapeutix stock have a consensus rating of "Strong Buy" and an average price target of $17.83, which forecasts a 46.57% increase in the stock price over the next year. The lowest target is $15 and the highest is $21.
Price Target: $17.83 (+46.57%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ocular Therapeutix stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 3 |
| Buy | 7 | 7 | 7 | 7 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Initiates $21 | Strong Buy | Initiates | $21 | +72.63% | Sep 15, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $22 → $20 | Buy | Maintains | $22 → $20 | +64.41% | Aug 6, 2025 |
| Needham | Needham | Strong Buy Maintains $14 → $15 | Strong Buy | Maintains | $14 → $15 | +23.30% | Aug 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +23.30% | May 29, 2025 |
| Needham | Needham | Strong Buy Maintains $15 → $14 | Strong Buy | Maintains | $15 → $14 | +15.08% | May 6, 2025 |
Financial Forecast
Revenue This Year
55.96M
from 63.72M
Decreased by -12.18%
Revenue Next Year
66.52M
from 55.96M
Increased by 18.87%
EPS This Year
-1.56
from -1.22
EPS Next Year
-1.52
from -1.56
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 71.2M | 87.0M | |||
| Avg | 56.0M | 66.5M | |||
| Low | 49.3M | 51.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 11.7% | 55.5% | |||
| Avg | -12.2% | 18.9% | |||
| Low | -22.6% | -8.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.50 | -1.12 | |||
| Avg | -1.56 | -1.52 | |||
| Low | -1.59 | -1.62 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.